The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Designing antibodies as therapeutics
Open accessAbstract
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit. These topics include enhancing antibodies for cancer, antibody delivery to organs such as the brain, gastrointestinal tract, and lungs, plus antibody developability challenges including immunogenicity risk assessment and mitigation and subcutaneous delivery. Machine learning has the potential, albeit as yet largely unrealized, for a transformative future impact on antibody discovery and engineering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning
Gainza, P., Sverrisson, F., Monti, F., Rodolà, E., Boscaini, D., Bronstein, M. M., & Correia, B. E. (2020) · Nature Methods · doi:10.1038/s41592-019-0666-6 · Cited by 834
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Self-citationIncreased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629
How Machine Learning Will Transform Biomedicine
Goecks, J., Jalili, V., Heiser, L. M., & Gray, J. W. (2020) · Cell · doi:10.1016/j.cell.2020.03.022 · Cited by 582
Tai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 439
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N. K., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 373
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Five computational developability guidelines for therapeutic antibody profiling
Raybould, M. I. J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810576116 · Cited by 357
Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
Zhu, Q., Chen, Z., Paul, P. K., Lu, Y., Wu, W., & Qi, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.001 · Cited by 353
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Manipulating extracellular tumour pH: an effective target for cancer therapy
Hao, G., Xu, Z. P., & Li, L. (2018) · RSC Advances · doi:10.1039/c8ra02095g · Cited by 341
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Kaplon, H., Chenoweth, A., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 331
Monoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T. M., Hassan, N. J., Gavarret, J., Bianchi, F. C., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 324
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308
Antibody Drug Conjugates for Cancer Therapy
Polakis, P. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009373 · Cited by 307
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., & Amantea, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0520-6 · Cited by 296
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006682 · Cited by 281
Design and Production of Bispecific Antibodies
Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J. (2019) · Antibodies · doi:10.3390/antib8030043 · Cited by 279
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
A review of Formulations of Commercially Available Antibodies
Strickley, R. G., & Lambert, W. J. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.017 · Cited by 271
Braig, F., Brandt, A., Goebeler, M., Tony, H.-P., Kurze, A.-K., Nollau, P., Bumm, T., Böttcher, S., Bargou, R. C., & Binder, M. (2017) · Blood · doi:10.1182/blood-2016-05-718395 · Cited by 268
Shah, D. K., & Betts, A. M. (2013) · mAbs · doi:10.4161/mabs.23684 · Cited by 262
Structure, Function, and Therapeutic Use of IgM Antibodies
Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F., & Peterson, M. S. (2020) · Antibodies · doi:10.3390/antib9040053 · Cited by 254
Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., Nicholas, N. D., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400217g · Cited by 245
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola, M., Sequeira, J., Seiça, R., Veiga, F., Serra, J., Santos, A. C., & Ribeiro, A. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.001 · Cited by 234
Logan, T., Simon, M. J., Rana, A., Cherf, G. M., Srivastava, A., Davis, S. S., Low, R. L. Y., Chiu, C.-L., Fang, M., Huang, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.002 · Cited by 233
The landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 229
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.008 · Cited by 225
de Jong, R. N., Beurskens, F. J., Verploegen, S., Strumane, K., van Kampen, M. D., Voorhorst, M., Horstman, W., Engelberts, P. J., Oostindie, S. C., Wang, G., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002344 · Cited by 219
Antibody structure prediction using interpretable deep learning
Ruffolo, J. A., Sulam, J., & Gray, J. J. (2022) · Patterns · doi:10.1016/j.patter.2021.100406 · Cited by 216
Sonoda, H., Morimoto, H., Yoden, E., Koshimura, Y., Kinoshita, M., Golovina, G., Takagi, H., Yamamoto, R., Minami, K., Mizoguchi, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.032 · Cited by 197
August, A., Attarwala, H. Z., Himansu, S., Kalidindi, S., Lu, S., Pajon, R., Han, S., Lecerf, J.-M., Tomassini, J. E., Hard, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01573-6 · Cited by 196
DeKosky, B. J., Lungu, O. I., Park, D., Johnson, E. L., Charab, W., Chrysostomou, C., Kuroda, D., Ellington, A. D., Ippolito, G. C., Gray, J. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525510113 · Cited by 192
Targeting cancer with antibody-drug conjugates: Promises and challenges
Dean, A. Q., Luo, S., Twomey, J. D., & Zhang, B. (2021) · mAbs · doi:10.1080/19420862.2021.1951427 · Cited by 190
Prihoda, D., Maamary, J., Waight, A., Juan, V., Fayadat-Dilman, L., Svozil, D., & Bitton, D. A. (2022) · mAbs · doi:10.1080/19420862.2021.2020203 · Cited by 190
Abramson, A., Frederiksen, M. R., Vegge, A., Jensen, B., Poulsen, M., Mouridsen, B., Jespersen, M. O., Kirk, R. K., Windum, J., Hubálek, F., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01024-0 · Cited by 185
Pulmonary Delivery of Biological Drugs
Liang, W., Pan, H. W., Vllasaliu, D., & Lam, J. K. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111025 · Cited by 184
Locke, K. W., Maneval, D. C., & LaBarre, M. J. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1551442 · Cited by 177
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
Ku, Z., Xie, X., Hinton, P. R., Liu, X., Ye, X., Muruato, A. E., Ng, D. C., Biswas, S., Zou, J., Liu, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03673-2 · Cited by 176
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Bispecific antibodies targeting mutant RAS neoantigens
Douglass, J., Hsiue, E. H.-C., Mog, B. J., Hwang, M. S., DiNapoli, S. R., Pearlman, A. H., Miller, M. S., Wright, K. M., Azurmendi, P. A., Wang, Q., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5515 · Cited by 171
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
Damelin, M. I., Zhong, W., Myers, J. S., & Sapra, P. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1624-3 · Cited by 171
Chaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 166
Self-citationGoldenberg, D. M., & Sharkey, R. M. (2019) · mAbs · doi:10.1080/19420862.2019.1632115 · Cited by 164
Papadopoulos, K. P., Isaacs, R., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162
A single molecular descriptor to predict solution behavior of therapeutic antibodies
Kingsbury, J. S., Saini, A., Auclair, S. M., Fu, L., Lantz, M. M., Halloran, K. T., Calero-Rubio, C., Schwenger, W., Airiau, C. Y., Zhang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb0372 · Cited by 162
Skokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 160
Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents
Dovgan, I., Koniev, O., Kolodych, S., & Wagner, A. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00306 · Cited by 159
Perry, S. L., & McClements, D. J. (2020) · Molecules · doi:10.3390/molecules25051161 · Cited by 158
Antibody complementarity determining region design using high-capacity machine learning
Liu, G., Zeng, H., Mueller, J., Carter, B., Wang, Z., Schilz, J., Horny, G., Birnbaum, M. E., Ewert, S., & Gifford, D. K. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz895 · Cited by 157
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, É., Massard, C., Robert, C., Ammari, S., de Baère, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0473 · Cited by 151
Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability
Maderuelo, C., Lanao, J. M., & Zarzuelo, A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105019 · Cited by 147
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
Third generation antibody discovery methods: in silico rational design
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00523k · Cited by 146
How PEGylation influences protein conformational stability
Lawrence, P. B., & Price, J. L. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.08.006 · Cited by 141
Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Neri, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0622 · Cited by 138
Slaga, D., Ellerman, D. A., Lombana, T. N., Vij, R., Li, J., Hristopoulos, M. L., Clark, R., Johnston, J., Shelton, A., Mai, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5775 · Cited by 137
Antibody Conjugates-Recent Advances and Future Innovations
Leung, D., Wurst, J., Liu, T., Martinez, R., Datta‐Mannan, A., & Feng, Y. (2020) · Antibodies · doi:10.3390/antib9010002 · Cited by 125
Belmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 125
Humanization of antibodies using a machine learning approach on large-scale repertoire data
Marks, C., Hummer, A. M., Chin, M., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab434 · Cited by 124
Hellmann, M. D., Bivi, N., Calderón, B., Shimizu, T., Delafontaine, B., Liu, Z. T., Szpurka, A. M., Copeland, V., Hodi, F. S., Rottey, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3716 · Cited by 118
Jiskoot, W., Hawe, A., Menzen, T., Volkin, D. B., & Crommelin, D. J. A. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.008 · Cited by 117
A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
Gai, J., Ma, L., Li, G., Zhu, M., Peng, Q., Li, X., Zhang, H., Zhang, Y., Chen, Y., Ji, W., et al. (2021) · MedComm · doi:10.1002/mco2.60 · Cited by 116
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
Jarvi, N. L., & Balu‐Iyer, S. V. (2021) · BioDrugs · doi:10.1007/s40259-020-00465-4 · Cited by 115
Biology drives the discovery of bispecific antibodies as innovative therapeutics
Nie, S., Wang, Z., Moscoso‐Castro, M., D'Souza, P., Lei, C., Xu, J., & Gu, J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa003 · Cited by 109
Investigation of the Influence of FcRn on the Distribution of IgG to the Brain
Garg, A., & Balthasar, J. P. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9129-9 · Cited by 108
Kamata‐Sakurai, M., Narita, Y., Hori, Y., Nemoto, T., Uchikawa, R., Honda, M., Hironiwa, N., Taniguchi, K., Shida-Kawazoe, M., Metsugi, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0328 · Cited by 106
Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRI
Jones, K. M., Randtke, E. A., Yoshimaru, E. S., Howison, C. M., Chalasani, P., Klein, R. R., Chambers, S. K., Kuo, P. H., & Pagel, M. D. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1029-7 · Cited by 103
Khetan, R., Curtis, R., Deane, C. M., Hadsund, J. T., Kar, U., Krawczyk, K., Kuroda, D., Robinson, S. A., Sormanni, P., Tsumoto, K., et al. (2022) · mAbs · doi:10.1080/19420862.2021.2020082 · Cited by 102
Surowka, M., Schäfer, W. M., & Klein, C. (2021) · mAbs · doi:10.1080/19420862.2021.1967714 · Cited by 101
Lucchi, R., Bentanachs, J., & Oller‐Salvia, B. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01448 · Cited by 100
Antibody-mediated drug delivery
Arslan, F. B., Öztürk, K., & Çalış, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120268 · Cited by 95
In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies
Bown, H. K., Bonn, C., Yohe, S. T., Yadav, D. B., Patapoff, T. W., Daugherty, A. L., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.015 · Cited by 94
Oral inhalation for delivery of proteins and peptides to the lungs
Fröhlich, E., & Salar-Behzadi, S. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.003 · Cited by 92
Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
Parray, H. A., Shukla, S., Perween, R., Khatri, R., Shrivastava, T., Singh, V., Murugavelu, P., Ahmed, S., Samal, S., Sharma, C., et al. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11488-4 · Cited by 90
Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?
Sousa, F., Castro, P. M., Fonte, P., Kennedy, P. J., Neves‐Petersen, M. T., & Sarmento, B. F. C. C. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1273345 · Cited by 89
Jimeno, A., Moore, K. N., Gordon, M. S., Chugh, R. K., Diamond, J. R., Aljumaily, R. M., Mendelson, D. S., Kapoun, A. M., Xu, L., Stagg, R., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0665-y · Cited by 85
Lai, P., Fernando, A., Cloutier, T. K., Gokarn, Y. R., Zhang, J., Schwenger, W. J., Chari, R. V. J., Calero‐Rubio, C., & Trout, B. L. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01073 · Cited by 81
How repertoire data are changing antibody science
Marks, C., & Deane, C. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.010181 · Cited by 80
Dyson, M. R., Masters, E. W., Pazeraitis, D., Perera, R. L., Syrjanen, J. L., Surade, S. B., Thorsteinson, N., Parthiban, K., Jones, P. C., Sattar, M., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1829335 · Cited by 80
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
Mimoto, F., Tatsumi, K., Shimizu, S., Kadono, S., Haraya, K., Nagayasu, M., Suzuki, Y., Fujii, E., Kamimura, M., Hayasaka, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108542 · Cited by 77
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
van Tetering, G., Evers, M., Chan, C., Stip, M. C., & Leusen, J. H. W. (2020) · Antibodies · doi:10.3390/antib9040070 · Cited by 75
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Lombaerde, E. D., Wever, O. D., & Geest, B. G. D. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188526 · Cited by 74
Oostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., van den Brakel, J. H. N., Rademaker, H. J., van Kessel, B., van den Noort, J. A., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0292-7 · Cited by 73
Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0194 · Cited by 72
Monoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulović, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 72
Ellwanger, K., Reusch, U., Fucek, I., Wingert, S., Ross, T., Müller, T. R., Schniegler‐Mattox, U., Haneke, T., Rajkovic, E., Koch, J., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1616506 · Cited by 69
Datta‐Mannan, A., Estwick, S. A., Zhou, C., Choi, H., Douglass, N. E., Witcher, D. R., Lu, J., Beidler, C. B., & Millican, R. L. (2020) · mAbs · doi:10.1080/19420862.2020.1770028 · Cited by 69
The clinical development of antibody–drug conjugates — lessons from leukaemia
Jabbour, E. J., Paul, S., & Kantarjian, H. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00484-2 · Cited by 67
Engineering Stability, Viscosity, and Immunogenicity of Antibodies by Computational Design
Kuroda, D., & Tsumoto, K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.011 · Cited by 66
Ducret, A., Ackaert, C., Bessa, J., Bunce, C., Hickling, T. P., Jawa, V., Kroenke, M. A., Lamberth, K., Manin, A., Penny, H. L., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1993522 · Cited by 66
Cook, E. M., Lindorfer, M. A., van der Horst, H. J., Oostindie, S. C., Beurskens, F. J. M., Schuurman, J., Zent, C. S., Burack, R., Parren, P. W. H. I., & Taylor, R. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600648 · Cited by 64
Panchal, A. P., Seto, P., Wall, R., Hillier, B. J., Zhu, Y. J., Krakow, J. L., Datt, A., Pongo, E., Bagheri, A., Chen, T.-H. T., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1792130 · Cited by 63
Epistasis in a Fitness Landscape Defined by Antibody-Antigen Binding Free Energy
Adams, R., Kinney, J. B., Walczak, A. M., & Mora, T. (2019) · Cell Systems · doi:10.1016/j.cels.2018.12.004 · Cited by 63
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
Kast, F., Schwill, M., Stüber, J. C., Pfundstein, S., Nagy‐Davidescu, G., Rodríguez, J. M. M., Seehusen, F., Richter, C. P., Honegger, A., Hartmann, K. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23948-6 · Cited by 63
Targeting regulatory T cells for immunotherapy in melanoma
Huang, L., Guo, Y., Liu, S., Wang, H., Zhu, J., Ou, L., & Xu, X. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00038-z · Cited by 61
Overdijk, M. B., Strumane, K., Beurskens, F. J. M., Buijsse, A. O., Vermot‐Desroches, C., Vuillermoz, B. S., Kroes, T., de Jong, B., Hoevenaars, N., Hibbert, R. G., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0044 · Cited by 58
When Therapeutic IgA Antibodies Might Come of Age
Sterlin, D., & Gorochov, G. (2020) · Pharmacology · doi:10.1159/000510251 · Cited by 57
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Knowles, S. P., Printz, M. A., Kang, D. W., LaBarre, M. J., & Tannenbaum, R. P. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1981286 · Cited by 57
Kavanaugh, W. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1699053 · Cited by 55
Chang, H. W., Frey, G., Liu, H., Xing, C., Steinman, L., Boyle, W. J., & Short, J. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020606118 · Cited by 54
Chiu, D., Tavaré, R., Haber, L., Aina, O. H., Vazzana, K., Ram, P., Danton, M. A., Finney, J., Jalal, S., Krueger, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0518 · Cited by 53
Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies
Tilegenova, C., Izadi, S., Yin, J., Huang, C., Wu, J., Ellerman, D. A., Hymowitz, S. G., Walters, B. T., Salisbury, C. M., & Carter, P. J. (2019) · mAbs · doi:10.1080/19420862.2019.1692764 · Cited by 52
Self-citationWang, B. T., Kothambawala, T., Wang, L., Matthew, T. J., Calhoun, S. E., Saini, A. K., Kotturi, M. F., Hernandez, G., Humke, E. W., Peterson, M. S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1132 · Cited by 52
DaSilva, J. O., Yang, K., Surriga, O., Nittoli, T., Kunz, A., Franklin, M. C., Delfino, F. J., Mao, S., Zhao, F. H., Giurleo, J. T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0009 · Cited by 51
Giugliani, R., Martins, A. M., Okuyama, T., Eto, Y., Sakai, N., Nakamura, K., Morimoto, H., Minami, K., Yamamoto, T., Yamaoka, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010938 · Cited by 51
The promise of bispecific antibodies: Clinical applications and challenges
Lim, S. M., Pyo, K., Soo, R. A., & Cho, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102240 · Cited by 47
Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n3127 · Cited by 47
Bispecifics and antibody–drug conjugates: A positive synergy
Maruani, A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.09.003 · Cited by 46
Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
Kamperschroer, C., Shenton, J. M., Lebrec, H. N., Leighton, J. K., Moore, P. A., & Thomas, O. (2020) · Journal of Immunotoxicology · doi:10.1080/1547691x.2020.1729902 · Cited by 46
Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets
Niamsuphap, S., Fercher, C., Kumble, S., Huda, P., Mahler, S. M., & Howard, C. B. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1781088 · Cited by 44
Utilizing Immunocytokines for Cancer Therapy
Runbeck, E., Crescioli, S., Karagiannis, S. N., & Papa, S. (2021) · Antibodies · doi:10.3390/antib10010010 · Cited by 44
Applications of Machine and Deep Learning in Adaptive Immunity
Pertseva, M., Gao, B., Neumeier, D., Yermanos, A., & Reddy, S. T. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-125021 · Cited by 43
Starr, C. G., Makowski, E. K., Wu, L., Berg, B., Kingsbury, J. S., Gokarn, Y. R., & Tessier, P. M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00280 · Cited by 43
Antibody–Drug Conjugates with Pyrrole‐Based KSP Inhibitors as the Payload Class
Lerchen, H., Wittrock, S., Stelte‐Ludwig, B., Sommer, A., Berndt, S., Griebenow, N., Rebstock, A., Johannes, S., Cancho‐Grande, Y., Mahlert, C., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807619 · Cited by 42
Innovations for Next-Generation Antibody-Drug Conjugates
(2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9 · Cited by 42
Nonclinical Immunogenicity Risk Assessment of Therapeutic Proteins
Tourdot, S., & Hickling, T. P. (2019) · Bioanalysis · doi:10.4155/bio-2018-0246 · Cited by 41
Wright, L., Barnes, T. J., & Prestidge, C. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119488 · Cited by 41
IgE Antibodies against Cancer: Efficacy and Safety
Chauhan, J., McCraw, A. J., Nakamura, M., Osborn, G., Sow, H. S., Cox, V. F., Stavraka, C., Josephs, D. H., Spicer, J. F., Karagiannis, S. N., et al. (2020) · Antibodies · doi:10.3390/antib9040055 · Cited by 40
Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies
Lou, H., & Hageman, M. J. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03022-y · Cited by 40
Anticalin® proteins: from bench to bedside
Deuschle, F., Ilyukhina, E., & Skerra, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1839046 · Cited by 38
Roberts, K. J., Cubitt, M. F., Carlton, T. M., Rodrigues-Duarte, L., Maggiore, L., Chai, R., Clare, S., Harcourt, K., MacDonald, T. T., Ray, K. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97236-0 · Cited by 38
Staton, T. L., Peng, K., Owen, R., Choy, D. F., Cabanski, C. R., Fong, A., Brunstein, F., Alatsis, K. R., & Chen, H. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0763-9 · Cited by 37
Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes
Vasiljeva, O. S., Menendez, E., Nguyen, M. T. L., Craik, C. S., & Kavanaugh, W. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-62339-7 · Cited by 37
Inhaled antibodies: Quality and performance considerations
Hickey, A. J., & Stewart, I. E. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940650 · Cited by 35
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
Ulitzka, M., Carrara, S. C., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaa025 · Cited by 32
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Kroenke, M. A., Milton, M., Kumar, S., Bame, E., & White, J. T. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00642-5 · Cited by 32
Matulonis, U. A., Moore, K. N., Martin, L. P., Vergote, I. B., Castro, C. M., Gilbert, L., Malek, K. S., Birrer, M. J., & O’Malley, D. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy285.157 · Cited by 30
An Overview of the Current ADC Discovery Landscape
Tumey, L. N. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9929-3_1 · Cited by 29
An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery
Madani, F., Hsein, H., Busignies, V., & Tchoreloff, P. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1689402 · Cited by 29
Staben, L. R., Chen, J., Cruz-Chuh, J. D., Rosario, G. D., Go, M. A. T., Guo, J., Khojasteh, S. C., Kozak, K. R., Li, G., Ng, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00691 · Cited by 22
Deonarain, M. P., & Yahioglu, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1858050 · Cited by 18
Formative Study on the Wearability and Usability of a Large-Volume Patch Injector
Lange, J., Schneider, A., Jordi, C., Lau, M., & Disher, T. C. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s337670 · Cited by 17
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Ramon, A., Ni, M., Predeina, O., Gaffey, R., Kunz, P., Onuoha, S., & Sormanni, P. (2025) · mAbs · doi:10.1080/19420862.2024.2442750 · Cited by 13
Tulika, T., Pedersen, R. W., Rimbault, C., Ahmadi, S., Rivera‐de‐Torre, E., Fernández‐Quintero, M. L., Loeffler, J. R., Bohn, M., Ljungars, A., Ledsgaard, L., et al. (2023) · Protein Science · doi:10.1002/pro.4821 · Cited by 11
In silico discovery of nanobody binders to a G-protein coupled receptor using AlphaFold-Multimer
Harvey, E. P., Smith, J. S., Hurley, J. D., Granados, A. J., Schmid, E. W., Liang-Lin, J. G., Zhang, H., Meara, E. M., Wren, E. K., Paul, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72093-5 · Cited by 7
Size distribution analysis of residual host cell DNA fragments in lentivirus by CGE-LIF
Wang, W., Gao, T., Luo, J., Guo, L., Li, X., Li, Y., & Chen, H. (2023) · ELECTROPHORESIS · doi:10.1002/elps.202200218 · Cited by 7
Metadata
- Authors
- Carter, P. J., & Rajpal, A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 185
- Issue
- 15
- Pages
- 2789-2805
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4286267340
- Cited by
- 267
- References
- 153
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.